These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18584778)

  • 1. Skin lesions and mast cells.
    Blood; 2008 Jul; 112(1):28. PubMed ID: 18584778
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
    Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
    Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
    J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
    Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
    Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
    Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On being metachromatic: mystique and misunderstanding in mastocytosis.
    Gotlib J
    Am J Hematol; 2009 Dec; 84(12):779-81. PubMed ID: 19899132
    [No Abstract]   [Full Text] [Related]  

  • 8. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
    de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
    Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement.
    Marton I; Pósfai É; Borbényi Z; Bödör C; Papp G; Demeter J; Korom I; Varga E; Bata-Csörgő Z
    Eur Rev Med Pharmacol Sci; 2015; 19(9):1607-9. PubMed ID: 26004600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kit Mutations: New Insights and Diagnostic Value.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib for systemic mast-cell disease.
    Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
    Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
    Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mastocytosis: Moving the Field to Precision and Personalized Medicine.
    Castells MC
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):xv-xvii. PubMed ID: 30007470
    [No Abstract]   [Full Text] [Related]  

  • 14. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
    Nakagomi N; Hirota S
    Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mastocytosis: advances in diagnosis and treatment.
    Hungness SI; Akin C
    Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
    Ustun C; DeRemer DL; Akin C
    Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
    Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
    Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.
    Broderick V; Waghorn K; Langabeer SE; Jeffers M; Cross NCP; Hayden PJ
    Leuk Res; 2019 Feb; 77():28-29. PubMed ID: 30612056
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Systemic mastocytosis].
    Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
    Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.